Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Radionuclide-labeled HER2-targeting Antibodies in HER2-positive Malignancies
NCT07023861Phase 1Enrolling by invitation
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-LNCab190, 89Zr-LNCab002 and 89Zr-LNCab072 in breast cancer, gastric cancer (GC) and urothelial carcinoma (UC) (3 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Tumor Uptake Value (SUVmax) and Number of Lesions Detected. Started Jul 2025; status: enrolling by invitation.
02
Drugs
89Zr-LNCab19089Zr-LNCab00289Zr-LNCab072
03
Conditions
breast cancergastric cancer (GC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07023861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023861.